Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Enterprise Value of -$170.4 million for Q1 2026, down 82.84% year-over-year from -$992.7 million in Q1 2025, and up 4.7% quarter-over-quarter from -$178.8 million in Q4 2025.
Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Enterprise Value data on file, last reported at -$170.4 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$170.4 million, down 82.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$170.4 million (down 82.84% YoY), and the FY2025 annual result was -$178.8 million, down 83.27% from the prior year.
- Enterprise Value climbed to -$170.4 million in Q1 2026 per IKT's latest filing, from -$178.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$3.2 million in Q3 2024 and troughed at -$178.8 million in Q4 2025.
- A 5-year average of -$54.2 million and a median of -$26.5 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 80.73% in 2024, then tumbled 2283.81% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$23.1 million in 2022, then surged by 42.51% to -$13.3 million in 2023, then plunged by 636.06% to -$97.5 million in 2024, then slumped by 83.27% to -$178.8 million in 2025, then climbed by 4.7% to -$170.4 million in 2026.
- Business Quant data shows IKT's Enterprise Value at -$170.4 million in Q1 2026, -$178.8 million in Q4 2025, and -$77.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -584.73 Mn |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | -170.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -170.37 Mn |
| Dec 31, 2025 | -178.76 Mn |
| Sep 30, 2025 | -77.32 Mn |
| Jun 30, 2025 | -87.67 Mn |
| Mar 31, 2025 | -93.18 Mn |
| Dec 31, 2024 | -97.54 Mn |
| Sep 30, 2024 | -3.24 Mn |
| Jun 30, 2024 | -7.94 Mn |
| Mar 31, 2024 | -9.75 Mn |
| Dec 31, 2023 | -13.25 Mn |
| Sep 30, 2023 | -16.83 Mn |
| Jun 30, 2023 | -20.94 Mn |
| Mar 31, 2023 | -25.72 Mn |
| Dec 31, 2022 | -23.05 Mn |
| Sep 30, 2022 | -26.53 Mn |
| Jun 30, 2022 | -32.21 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | -40.75 Mn |
| Sep 30, 2021 | -44.85 Mn |
| Jun 30, 2021 | -46.84 Mn |